Evidence map›Paper›PMID 20631493›Full record

ReviewJournal of endocrinological investigation2010

Pathogenesis of Graves' orbitopathy: a 2010 update.

T J Smith

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of endocrinological investigation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Machine Learning-Based Cytokine Endotyping of Thyroid Eye Disease.Investigative ophthalmology & visual science · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Graves' disease post-COVID-19 m-RNA vaccine in pediatric age group.Asia Oceania journal of nuclear medicine & biology · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Insulin-Like Growth Factor Pathway and the Thyroid.Frontiers in endocrinology · 2021
    Review
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

T J SmithDepartments of Ophthalmology and Visual Sciences and Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48105, USA. terrysmi@med.umich.edu
University of Michigan–Ann Arbor · US

Funding

REGULATION OF RETROOCULAR CONNECTIVE TISSUER01EY008976 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SMITH, TERRY J · 1993 to 2020
$6.4M
FUNCTIONAL DIVERSITY OF ORBITAL FIBROBLASTSR01EY011708 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SMITH, TERRY J · 1997 to 2011
$4.3M
Immunoglobulin Activation of FibroblastsR01DK063121 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SMITH, TERRY J · 2004 to 2012
$3.2M
NEI NIH HHS EY011708NEI NIH HHS EY08976NEI NIH HHS R01 EY008976NEI NIH HHS R01 EY011708NIDDK NIH HHS DK063121NIDDK NIH HHS R01 DK063121
6 · The paper itself

Abstract

The most important of the extra-thyroidal manifestations of Graves' disease, Graves' orbitopathy (GO), remains a vexing clinical problem. Treatment of severe active disease has been limited to steroids or radiotherapy. In the relatively rare case where vision is threatened, emergent decompression surgery can be performed. The proptosis, motility, or cosmetic concerns associated with stable GO are commonly remedied with surgical intervention. Substantial obstacles have prevented the development of specific medical therapies for GO, in large part resulting from poor understanding of disease pathogenesis and the absence of preclinical animal models. Fundamental aspects of GO's etiology have been uncovered from studies based in cell culture, extensive analysis of blood constituents, and detailed examination of orbital contents collected at the time of surgical intervention. Many of the published reports resulting from these studies are descriptive and all have failed to yield unifying concepts that integrate the anatomically divergent manifestations of Graves' disease. This brief review covers recent findings of several research groups. While major breakthroughs continue to occur in closely related autoimmune diseases, progress in identifying the pathogenic mechanisms relevant to GO has been limited. As emerging insights into human autoimmunity becomes applied to the study of Graves' disease, we anticipate that improved therapeutic strategies will find their way to our patients with GO.

Indexed as

Antigens, CD34AutoimmunityBone Marrow CellsFibroblastsGraves DiseaseGraves OphthalmopathyHumansIodine RadioisotopesMicrofilament ProteinsPhenotypeReceptor, IGF Type 1Receptors, ThyrotropinAntigens, CD34Iodine RadioisotopesLSP1 protein, humanMicrofilament ProteinsReceptor, IGF Type 1Receptors, Thyrotropin

Identifiers

PMID20631493
PMCPMC6779038
OpenAlexW2153159377

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.